Format

Send to

Choose Destination
See comment in PubMed Commons below
Curr Treat Options Oncol. 2012 Dec;13(4):437-50. doi: 10.1007/s11864-012-0208-2.

The spectrum of vaccine therapies for patients with glioblastoma multiforme.

Author information

1
Advantagene Inc, 440 Lexington St, Auburndale, MA 02466, USA. lkaguilar@advantagene.com

Abstract

OPINION STATEMENT:

Glioblastoma multiforme (GBM) is the most common primary malignant tumor of the central nervous system (CNS) and one of the most lethal cancers in adults and children. Despite aggressive treatment with surgery, radiation, and chemotherapy, median survival is less than 15 months and overall survival is less than 10 % at 5 years. Development of therapeutics for malignant gliomas has been hampered by their natural complexity as well as protective mechanisms unique to the CNS. Better understanding of the pathogenesis of GBM is opening the path to novel, specific-targeted therapies. Recently, multiple immunotherapy approaches have been acquiring substantial indication of therapeutic efficacy with a very safe profile. Examples of the leading clinical approaches for GBM will be discussed in detail in this review.

PMID:
22903697
PMCID:
PMC3499675
DOI:
10.1007/s11864-012-0208-2
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer Icon for PubMed Central
    Loading ...
    Support Center